arrow
D

Dong Ji

Chinese PLA General Hospital
H指数:28
被引数:3,887

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Safety, Tolerability and Antiviral Activity of GST-HG131 in Chronic Hepatitis B: A Randomized, Double-Blind Phase IIa Study

GST-HG131在慢性乙型肝炎中的安全性、耐受性及抗病毒活性:一项随机、双盲IIa期研究

2026-10-280
OAAI
HBsAg Quantification-Based Models for Predicting Hepatocellular Carcinoma Risk in Nucleos(t)ide Analogs-Experienced Patients With Chronic Hepatitis B: The HBsAg-HCC Score

HBsAg定量模型预测核苷类似物治疗经验性慢性乙型肝炎患者发生肝细胞癌的风险:HBsAg-HCC评分

2026-04-030
PRE
Assessment of significant hepatic damage in young patients with chronic hepatitis B to initiate the antiviral treatment: The APLB score

评估慢性乙型肝炎年轻患者显著肝损伤以启动抗病毒治疗的指标:APLB评分

2025-07-050
PRE
RNase1-driven ALK-activation is an oncogenic driver and therapeutic target in non-small cell lung cancer

RNase1驱动的ALK激活是非小细胞肺癌中的致癌驱动因子和治疗靶点。

2025-04-180
OA
Efficacy and safety of switching from entecavir to tenofovir alafenamide in chronic hepatitis B patients with low-level viremia: a real-world 48-week extension study

从恩替卡韦切换到替诺福韦alafenamide在慢性乙型肝炎患者低水平病毒血症的疗效和安全性: 一个真实世界的48周扩展研究

2025-02-040
OAAI
aMAP Score and Its Combination With Liver Stiffness Measurement Accurately Assess Liver Fibrosis in Chronic Hepatitis B Patients
2023-11-017
PRE
Development and validation of a machine learning-based model for varices screening in compensated cirrhosis (CHESS2001): an international multicenter study

代偿性肝硬化静脉曲张筛查基于机器学习的模型的开发和验证 (CHESS2001): 一项国际多中心研究

2023-03-014
PRE
Corticosteroid plus glycyrrhizin therapy for chronic drug- or herb-induced liver injury achieves biochemical and histological improvements: A randomised open-label trial

糖皮质激素联合甘草酸治疗慢性药物或草药诱导的肝损伤可实现生化和组织学改善: 一项随机开放标签试验

2022-03-3127
OA